The company’ss Series A funding round was led by Ecoloab and saw participation from Pravega Ventures, Axilor Ventures, Techstars, and other angel investors
The startup will utilise the funding to refine its AI capabilities, expand its footprint and increase its reach to more customers
Founded in 2019, Leucine helps pharmaceutical companies leverage AI to digitise manufacturing workflows by replacing traditional paper-based compliance procedures with a digital-first approach
B2B software-as-a-service (SaaS) platform Leucine has raised $7 Mn as part of its Series A funding round led by Ecoloab. The round also saw participation from Pravega Ventures, Axilor Ventures, Techstars, and other angel investors.
The startup plans to utilise the funds to scale up its tech stack and refine its AI capabilities. The fresh capital will also be deployed to expand its footprint and increase its reach to more customers.
“Vivek and Mustaq have been relentless in their mission to make pharma manufacturing safer. This latest funding round will enable Leucine to bring the power of LLMs and associated technologies to make significant advances in pharma manufacturing. We couldn’t be happier to support them in this quest,” said Pravega Ventures’ cofounder and partner Rohit Jain.
Chiming in, Leucine cofounder and CEO Vivek Gera said, “We’re just scratching the surface; our vision is to leverage AI and technology to bring safe medicine to patients across the world.”
Founded in 2019 by Gera and Mustaq Singh Bijral, Leucine helps pharmaceutical companies leverage AI to digitise manufacturing workflows by replacing traditional paper-based compliance procedures with a digital-first approach. Headquartered in New Jersey, the platform also offers actionable insights into the whole manufacturing process through its dashboard to produce safer and more effective medicines.
Meanwhile, the company also announced the beta launch of its AI framework, Leucine10x, which aims to serve as a co-pilot in pharmaceutical manufacturing processes.
Leucine claims to offer real-time performance monitoring and compliance management for pharma manufacturers to alleviate concerns around batch recalls. Leucine claims that its platform can be deployed in under eight weeks.
“Our models are trained on a wealth of pharma data, which allows the platform to create custom workflows enriched with GxP compliance measures, enabling us to deliver unparalleled value at breakneck speed… A batch execution procedure is the single most important document in pharma manufacturing. This rapid digitisation capability reduces the digitisation cycle of a batch record from 6-8 months to 3-5 days,” Gera claimed.
GxP is the acronym for ‘good practices’ and covers regulations and guidelines applicable to the life sciences industry to ensure stringent quality standards are met within pharma production.
The startup claims that its products are currently deployed at more than 300 pharma manufacturing facilities spanning 10 countries, including India, the US, Mexico, Brazil, the UAE, among others.
It claims to have nearly doubled the number of manufacturing facilities using its product in the past 12 months.
Leucine largely competes with global players in the healthtech SaaS segment. However, the startup’s niche lies with the global pharma 4.0 space, which is projected to become a $63.17 Bn market opportunity by 2032.
